CD47 and neoplasm: In addition, researchers developed plasmid CAR (pCAR) containing nano porters (NP), which target TAMs and generate CAR-Ms in-vivo and demonstrated that the combination of NP-pCAR and anti-CD47 showed the most potent anti-tumor capacity compared to NP-pCAR or anti-CD47 alone.